NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
Clinical Trials
8 trialsNCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT05459844 2025-09-05
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Phase 3 Active not recruiting
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT00241020 2016-04-12
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 3 Completed
NCT00412061 2014-11-21
RADIANT-2
Novartis
Phase 3 Completed
NCT00690430 2013-07-30
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Novartis
Phase 3 Completed
NCT00006269 2012-05-25
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Novartis
Phase 3 Terminated